Month: September 2021

Second Phase 2 trial of omilancor in Crohn’s disease (CD), expected to initiate in 2021 Awarded a $3 million NIH R01 grant from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases to fund this study BLACKSBURG, Va., Sept. 20, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral small-molecule therapeutics for patients with autoimmune diseases, today announced a research collaboration with the Icahn School of Medicine at Mount Sinai to conduct a Phase 2 trial of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, in patients with moderate-to-severe Crohn’s disease (CD). “Entering this partnership with the Icahn School of Medicine at Mount Sinai highlights our...

Fast-Acting And Long-Lasting Sleep Formula Promotes Quicker Sleep Onset And A Restful NightPLUS Dual Action Sleep GummiesPlus Products Reveals Dual Action Sleep gummies featuring first combined fast acting, long lasting formulationSAN MATEO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”), a cannabis and hemp-branded products company in California, today announced the launch of its Dual Action Sleep gummies, featuring a two part formulation that starts working in eight minutes, while also lasting throughout the night. Highlights:Two new gummies, Dual Action Sleep Cloudberry and Dual Action Sleep Lychee feature the all-new Dual Action Formula. The new and improved Dual Action formulation uses fast acting nano-emulsion that starts the bedtime process...

LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that four abstracts highlighting LYR-210 results in chronic rhinosinusitis and the XTreo™ platform have been selected for presentations at the upcoming 28th Congress of European Rhinologic Society (ERS) and the 67th Annual Meeting of the American Rhinologic Society (ARS), held September 26-30 and October 1-2, 2021 respectively. New LYR-210 data from the LANTERN 6-month follow-up study and recently completed pharmacokinetic study, will be the...

EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will be added to the Russell Microcap® Index, effective after the U.S. market opens today, September 20, 2021. The Russell Microcap Index measures the microcap segment of the U.S. equity market, consisting of the smallest 1,000 securities in the small-cap Russell 2000® Index, plus the next 1,000 smallest eligible securities by market cap. The Index is completely reconstituted annually to ensure new and growing equities are reflected and companies continue to reflect appropriate capitalization and value characteristics. “We are honored and thrilled to...

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. The conference will be held in a virtual meeting format. The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing...

MONTREAL, Sept. 20, 2021 (GLOBE NEWSWIRE) — TOMAGOLD CORPORATION (TSXV: LOT) (OTCQB: TOGOF) (“TomaGold” or the “Corporation”) is pleased to provide an update on the drilling program on its wholly-owned Obalski property, located 3 km south of Chibougamau. The program, which started on July 10, 2021, has been expanded from 10,000 metres to 11,500 metres of drilling following reassessment of the drill targets. Drilling has been temporarily paused and will resume in October. As at September 6, 2021, eight holes and two hole extensions had been drilled, for a total of 4,693 metres. A total of 751 samples have been collected and sent to the ALS Global laboratory in Val-d’Or for analysis, of which 135 will be analysed by both fire assay and cyanidation for the purpose of comparing and validating whether there is a significant difference...

– Presentations highlight progress in the development of losmapimod for FSHD – CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters and presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) during the Virtual Congress of the World Muscle Society. These results highlight progress made in the development of losmapimod for the treatment of FSHD as well as imaging modalities for the management of FSHD. “FSHD is a serious, relentless and debilitating disease for which there are currently no approved therapies,” said Chris Morabito, MD, Fulcrum’s chief medical officer. “The results from the Phase...

TORONTO, Sept. 20, 2021 (GLOBE NEWSWIRE) — EnviroGold Global Limited (“EnviroGold Global” or the “Company”) (CSE: NVRO), a Clean Technology Company accelerating the world’s transition to a circular-resource economy through the production of metals without mining, is pleased to announce the execution of binding commercial agreements adding the Buchans River Delta Reclamation Project (the “Buchans Project”) to its portfolio of Environmental Remediation and Asset Reclamation Projects. The Buchans Project includes approximately 1,225 hectares (3,025 acres) of mining claims located in the Canadian Province of Newfoundland and Labrador. Consistent with the Company’s strategy of reclaiming valuable and strategic commodities while remediating legacy and other environmental hazards, EnviroGold Global anticipates commissioning recovery and...

AUSTIN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading Infrastructure and Environmental solutions provider, announced today that senior management of the Company will participate in the D.A. Davidson 20th Annual Diversified Industrials & Services Virtual Conference on Wednesday, September 22, 2021. About Atlas Technical Consultants Headquartered in Austin, Texas, Atlas is a leading provider of Environmental (ENV), Testing, Inspection & Certification (TIC), Engineering & Design (E&D), and Program, Construction, and Quality Management (PCQM) services. Under the name Atlas Technical Consultants, we offer solutions to public and private sector clients in the transportation, commercial, water, government, education, and industrial markets....

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:40 AM (ET). The conference is being held September 27-30, 2021. A live audio webcast will be available at https://wsw.com/webcast/cantor12/avxl.ob/2514820 or on the Company’s website at www.anavex.com. A webcast replay will be accessible for 30...